Institutional members access full text with Ovid®

Share this article on:


Greenberg, Benjamin M.; Khatri, Bhupendra O.; Kramer, John F.

CONTINUUM: Lifelong Learning in Neurology: October 2010 - Volume 16 - Issue 5, Multiple Sclerosis - p 58-77
doi: 10.1212/

For a disease whose cause remains elusive, there has been a paradoxical growth in multiple sclerosis (MS) therapeutics. During the past 17 years, six therapeutic drugs for MS were brought to market. All of these disease-modifying therapies (DMTs) have shown a beneficial effect in reducing the number of exacerbations in double-blind placebo-controlled trials, and three drugs (subcutaneous [SC]/IM interferon beta-1a, natalizumab) have been shown to reduce relapses, decrease MRI activity, and reduce the risk of sustained disability after 2 years of treatment. No controlled studies exist to show long-term benefit with any of the current DMTs. Immunosuppressive drug (ISD) therapies continue to play a role in the management of patients who fail to respond to immunomodulatory agents. These agents, however, have shown mixed data in terms of efficacy and put patients at higher risk for the development of secondary cancers. Plasma exchange for severe relapses not responsive to corticosteroid therapy has regained interest in the past few years. Furthermore, six new agents that will dramatically impact our ability to prevent disability in patients with MS are in late-stage or have completed phase 3 clinical development. Determining the risk-benefit calculations that we will need to employ toward these new drugs and the algorithms for switching therapies will be critical issues in the next 5 years. This article highlights the clinical efficacy of the current DMTs/ISDs and discusses the current treatment options for clinically isolated syndrome, relapsing-remitting MS (RRMS), and exacerbations of RRMS. It also addresses the management of a suboptimal response to the DMTs; discusses the challenge of primary progressive MS; and presents an overview of emerging therapeutic options.

Note: Text referenced in the Quintessentials Preferred Responses, which appear later in this issue, is indicated in yellow shading throughout this article.

Relationship Disclosure: Dr Greenberg has received personal compensation for activities with Biogen Idec; DioGenix, Inc.; EMD Serono, Inc.; and Teva Neuroscience. Dr Khatri has received personal compensation for consulting, speaking, and advisory board activities from Bayer; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; and Teva Neuroscience. Dr Khatri has received research support from Bayer; Biogen Idec; Covidian; Medtronic Inc.; Novartis; Pfizer Inc; and Teva Neuroscience. Mr Kramer has received personal compensation for speaking engagements from Bayer; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; and Teva Neuroscience.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Greenberg discusses the investigational use of multiple agents, including alemtuzumab, BG00012, daclizumab, FTY720, laquinimod, and teriflunomide. Dr Khatri and Mr Kramer have nothing to disclose.

© 2010 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website